Key result
Clonal hematopoiesis links cardiovascular disease and solid tumors, driving elevated risk in cancer survivors.
This review highlights clonal hematopoiesis as a potential shared risk factor and mechanistic link between solid organ cancers and cardiovascular disease.
Emerging evidence suggests a dynamic relationship exists between cancer and cardiovascular disease (CVD). CVD is common among cancer survivors; however, it also may increase the risk of developing cancer. The underlying factors driving this connection remain poorly understood. Aging, chronic inflammation, and perturbed immune signaling are shared hallmarks of cancer and CVD. Clonal hematopoiesis (CH), the age-related accumulation of somatic mutations in hematopoietic cells leading to cells with a growth advantage, is associated with immune dysregulation in elderly people. Growing evidence suggests that CH is a risk factor for CVD. Although the link between CH and hematological cancer is well established, its relationship to solid organ cancers is far less understood. This review provides an in-depth analysis of the evidence linking CH with solid organ malignancies and explores its role as a shared risk factor for the development of both CVD and cancer. Furthermore, it discusses the potential mechanisms by which CH may contribute to CVD among cancer survivors.
No takes yet. Share an insight, caveat, or question.
Evans et al. (2025) conducted a review in Cancer and Cardiovascular Disease. Clonal hematopoiesis was evaluated. Clonal hematopoiesis is a shared risk factor for the development of both cardiovascular disease and solid organ malignancies, and may contribute to cardiovascular disease among cancer survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: